Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

ALNY Alnylam Pharmaceuticals

202.610
+5.220+2.64%
Close 09/27 16:00 ET
203.060
+0.450+0.22%
Post Mkt Price 09/27 16:41 ET
High
204.950
Open
201.330
Turnover
163.44M
Low
200.650
Pre Close
197.390
Volume
806.75K
Market Cap
24.32B
P/E(TTM)
Loss
52wk High
236.800
Shares
120.03M
P/E(Static)
Loss
52wk Low
117.580
Float Cap
23.30B
Bid/Ask %
-81.82%
Historical High
236.800
Shs Float
114.99M
Volume Ratio
1.24
Historical Low
3.650
Dividend TTM
--
Div Yield TTM
--
P/B
138.11
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.70%
Amplitude
2.18%
Avg Price
202.592
Lot Size
1
Float Cap
23.30B
Bid/Ask %
-81.82%
Historical High
236.800
Shs Float
114.99M
Volume Ratio
1.24
Historical Low
3.650
Dividend TTM
--
P/B
138.11
Dividend LFY
--
Turnover Ratio
0.70%
Amplitude
2.18%
Avg Price
202.592
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
CEO: Dr. Yvonne L Greenstreet
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...